Saint Apollinaire, France

Audrey Ressejeac

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Crossject. Active years: 2022.


% Patents Active = 100.0


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Audrey Ressejeac: Innovator in Pharmaceutical Solutions

Introduction

Audrey Ressejeac is a notable inventor based in Saint Apollinaire, France. She has made significant contributions to the field of pharmaceuticals, particularly in the development of solutions for critical medical conditions. Her innovative work focuses on creating effective treatments for emergencies such as anaphylactic shocks and cardiac arrests.

Latest Patents

Audrey holds a patent for an adrenaline pharmaceutical solution designed for an injection device. This solution includes adrenaline or a pharmaceutically-acceptable salt thereof, vitamin E TPGS, a chelating agent, and a solvent. The method is particularly relevant for treating anaphylactic shocks, cardiac arrests, asthma, and cardiocirculatory distresses. Additionally, it encompasses an injection kit that includes both the injection device and the pharmaceutical solution.

Career Highlights

Audrey is currently associated with Crossject, a company that specializes in innovative medical solutions. Her work at Crossject has allowed her to focus on developing life-saving pharmaceutical products that can be used in emergency situations.

Collaborations

Audrey collaborates with talented professionals in her field, including Eric Teillaud and Nicolas Baumard. These partnerships enhance her research and development efforts, contributing to the advancement of medical technologies.

Conclusion

Audrey Ressejeac is a pioneering inventor whose work in pharmaceutical solutions is making a significant impact on emergency medical care. Her dedication to innovation continues to drive advancements in the treatment of critical health conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…